All In Biotech

Drug Trial Radar · NCT06680921

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

A Randomized, Open-label, Phase III Study of SIM0270 Combined With Everolimus Versus Treatment of Physician's Choice in Patients With CDK4/6 Inhibitors Previously Treated , ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 482 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

482

Actual

Start

Nov 14, 2024

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Sponsor type
Industry
Collaborators
Nanjing Zaiming Pharmaceutical Co., Ltd.
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • SIM0270Drug

    Experimental

  • Everolimus (Afinitor®)Drug

    Experimental and Active comparator

  • Exemestane tabletsDrug

    Active Comparator

  • Fulvestrant injectionDrug

    Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival(PFS) , as assessed by blinded independent review committee(BIRC) according to RECIST1.1Time frame: 2 year

Locations

57 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hispital of Bengbu Medical University

    Bengbu, Anhui, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • The First Affiliated Hispital of Anhui Medical University

    Hefei, Anhui, China

  • Maanshan People's Hospital

    Maanshan, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The First Medical Center of PLA Ggeneral Hospital

    Beijing, Beijing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Guangdong Maternal and Child Health Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Zhongshan City People's Hospital

    Zhongshan, Guangdong, China

  • Guangxi Medical University Cancer hospital

    Nanning, Guangxi, China

  • First Hospital Of Qinhuangdao

    Qinhuangdao, Hebei, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Anyang Tumor Hospital

    Anyang, Henan, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China

  • The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Wuhan University Zhongnan Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • The First PEOPLE'S HOSPITAL OF CHANGDE CITY

    Changde, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The First Affiliated Hospital of JINZHOU Medical University

    Jinzhou, Liaoning, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.